Adv Neurobiol 13:133171 Martn-Rufin M, Nascimento-Gomes R, Higuero A et al (2014) Both GLS silencing and GLS2 overexpression synergize with oxidative stress against proliferation of glioma cells
The complete side effect frequency breakdown from Phase 2 trials: Very Common (20%+ of patients at 12mg dose) Nausea: 28% Typically mild to moderate, peaks weeks 4-8, usually resolves by week 12 Diarrhea: 24% Usually transient (1-3 weeks), rarely severe Constipation: 21% Paradoxically coexists with diarrhea in different patients Common (10-20% of patients) Vomiting: 17% Decreased appetite: 16% (beyond therapeutic effect) Injection site reactions: 14% Fatigue: 13% Dyspepsia (indigestion): 12% Headache: 11% Uncommon (2-10% of patients) Abdominal pain: 8% Dizziness: 7% Gastroesophageal reflux: 6% Hypoglycemia in diabetics on other medications: 5% Increased heart rate (average 2-4 bpm): 4% Hair thinning/loss: 3% (typically temporary) Rare but Serious (Under 2%) Pancreatitis: 0.3% (3 cases out of 1,032 patients, all resolved with discontinuation) Gallbladder events: 1.4% (expected with rapid weight loss regardless of method) Acute kidney injury: 0.7% (all cases associated with severe dehydration) KEY TAKEAWAY: About 30% experience meaningful nausea in the first 4-8 weeks
Randomized clinical studies in rodents and older adults show that glutathione acts in concert with the independent actions to two key precursors, glycine and and cysteine, to improve an array of biomarkers associated with the hallmarks of aging
Increased Fat Oxidation : L-Carnitine helps transport fatty acids into the mitochondria, where they are burned for energy
Risk and Handling Precautions Risk Tier: MODERATE This rating reflects both peptides' bioactive activity at angiogenic and cytoskeletal signaling pathways in preclinical models, the absence of established human safety profiles for either compound, and the additional handling considerations specific to intranasal formulations
